TickerFacts.

Upstream Bio, Inc. (UPB): Revenue

Annual figures by period end, from SEC filings.

$2.85M
Year ended 2025-12-31
$3.16M
Trailing 12 months to 2026-06-30
2023-12-31: $2.38M2024-12-31: $2.37M2025-12-31: $2.85M$2.85M
2023-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$2.85M+20.4%2026-03-26, From 2025-01-01
2024-12-31$2.37M-0.4%2026-03-26, From 2024-01-01
2023-12-31$2.38Mn/a2025-03-12, From 2023-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Upstream Bio, Inc. (UPB)2025-12-31$2.85M+20.4%
Cartesian Therapeutics, Inc. (RNAC)2025-12-31$2.80M-92.8%
Xenetic Biosciences, Inc. (XBIO)2025-12-31$2.98M+19.0%
TherapeuticsMD, Inc. (TXMD)2025-12-31$3.02M+71.6%
GeoVax Labs, Inc. (GOVX)2025-12-31$2.49M-37.1%
Camp4 Therapeutics Corp (CAMP)2025-12-31$3.50M+436.5%
Marker Therapeutics, Inc. (MRKR)2025-12-31$3.55M-46.2%
Korsana Biosciences, Inc. (KRSA)2025-12-31$2.07M+3.7%
Dianthus Therapeutics, Inc. (DNTH)2025-12-31$2.04M-67.3%

Compare UPB, RNAC, XBIO, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗